z-logo
open-access-imgOpen Access
Oxidative, Inflammatory, Angiogenic Markers and Vitamin D Status in Pre- and Postmenopausal Breast Cancer Egyptian Patients
Author(s) -
Safinaz E. El-Toukhy,
Omar M.E. Abdel-Salam,
Amr M. M. Ibrahim,
Eman R. Youness
Publication year - 2021
Publication title -
biomedical and pharmacology journal/biomedical and pharmacology journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.191
H-Index - 18
eISSN - 2456-2610
pISSN - 0974-6242
DOI - 10.13005/bpj/2186
Subject(s) - medicine , metastatic breast cancer , breast cancer , cancer , malondialdehyde , gastroenterology , uric acid , nitric oxide , oncology , oxidative stress , endocrinology
We aimed to investigate the oxidative, inflammatory, angiogenic biomarkers and vitamin D status in serum of Egyptian patients with cancer breast. Seventy patients with known cancer breast (non-metastatic and metastatic) were evaluated and compared to and healthy women. We observed significant decreases in serum malondialdehyde, nitric oxide, total antioxidant capacity (TAC) and uric acid in patients with non-metastatic and metastatic cancer. Subjects with metastatic cancer exhibited significantly lower nitric oxide and TAC compared with non- metastatic cancer. Meanwhile, significant increases in serum VEGF, HGF, and MMP-9 occurred in both pre- and post-menopausal patients with either non-metastatic or metastatic cancer with significantly higher values in metastatic disease. Significant increase in serum TNF-α was observed with significantly higher values in metastatic disease. Serum 25 hydroxy vitamin D (VITD) decreased in both types of cancer with significantly lower values in pre-menopausal compared to post-menopausal patients. Pre-menopausal subjects showed significantly lower serum VITD level compared to their post-menopaual counterparts, but there were no differences between those who were –ve for PR receptor and +ve patients. These results suggest that vascular and inflammatory markers VEGF, HGF, MMP-9 and TNF-α increased in serum in advanced stages of breast cancer and could monitor disease progression and/or severity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here